Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Phase I Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

The purpose of this clinical research study is to establish the maximum tolerated dose and recommended Phase II dose of Erbitux™ in combination with Irinotecan in pediatric and adolescent patients with refractory solid tumors.

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of a solid tumor which has progressed on, or following standard therapy, or for which no standard effective therapy is known.
• Children age 1-18 years.

Exclusion Criteria:

• Presence of active infection.
• Requirement to receive concurrent chemotherapy immunotherapy, radiotherapy, or any other investigational drug while on study.
• Inadequate bone marrow, hepatic, or renal function.